Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma

Future Medicinal Chemistry

Volumn 3, Issue 13, 2011, Pages 1703-1718

  Lechuga Ballesteros, David ^a   Noga, Brian ^a   Vehring, Reinhard ^a,b   Cummings, R Harris ^a   Dwivedi, Sarvajna K ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOAIR; AEROCORT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESAL; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CARMOTEROL; CORTICOSTEROID; DUOVA; FENOTEROL PLUS IPRATROPIUM BROMIDE; FENOVENT; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORACORT; FORMODUAL; FORMOTEROL; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; FOSTER; GLYCOPPYROLATE; GLYCOPYRRONIUM BROMIDE; INDACATEROL; INNOVAIR; IPRAMOL; IPRATEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LAS 40464; MOMETASONE FUROATE; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PT 003; QMF 149; QVA 149; RESPIMAT; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; SEROFLO; TIOTROPIUM BROMIDE; TRIOHALE; UNCLASSIFIED DRUG; VILANTEROL;

AEROSOL; ASTHMA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CRYSTALLIZATION; DEVICE; DRUG FORMULATION; HUMAN; IN VITRO STUDY; METERED DOSE INHALER; MONOTHERAPY; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SPRAY DRYING;

ASTHMA; DRUG THERAPY, COMBINATION; HUMANS; METERED DOSE INHALERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 80053176667     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.133     Document Type: Review

References (61)

1. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 34(3), 757-769 (2009).
2. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br. J. Pharmacol. 155(3), 291-299 (2008).
3. Marjason J, Orevillo CJ, St Rose E et al. Assessment of safety and pharmacokinetic profile of a novel fixed combination of glycopyrrolate and formoterol HFA pMDI in healthy volunteers. Am. J. Respir. Crit. Care Med. 181, A4455 (2010).
4. Vehring R, Hartman MSS, Schultz R et al. Glycopyrrolate and formoterol fumarate monotherapy and combination metered dose inhalers with high dose uniformity and stable aerosol properties. Am. J. Respir. Crit. Care Med. 181, A4452 (2010).
5. Reisner C, Forgaty C, Spangenthal S et al. Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared with its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Am. J. Respir. Crit. Care Med. 183, A6435 (2011).
6. Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int. J. Clin. Practise 63(8), 1136-1149 (2009).
7. Cazzola M, Matera MG. To add, or not to add an inhaled corticosteroid in moderate COPD : that is the question. Chest 134, 223-225 (2008).
8. Wu L, da Rocha SRP. Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation. Langmuir 23(24), 12104-12110 (2007). (Pubitemid 350197378)
9. Lavorini F, Corrigan CJ, Barnes PJ et al. Retail sales of inhalation devices in European countries: So much for a global policy. A report of the Aerosol Drug Management Improvement Team (ADMIT).Resp. Med. 105(7), 1099-1103 (2011).
10. Crompton GK, Barnes PJ, Broeders M et al. The need to improve inhalation technique in Europe: a report from the aerosol drug management improvement team. Resp. Med. 100(9), 1479-1494 (2006). (Pubitemid 44109117)
11. Singh GJP, Poochikian G. Development and approval of inhaled respiratory drugs: A US regulatory science perspective. In: Controlled Pulmonary Drug Delivery, Advances in Delivery Science and Technology. 489-527 (2011).
12. Vervaet C, Byron P. Drug-surfactant-propellant interactions in HFA-formulations. Int. J. Pharm. 186, 13-30 (1990).
13. Smyth DCH. Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2(1), 53-74 (2005).
14. UNO. United Nations Environmental Programme (Ozone Secretariat).Handbook for the International Treaties for the Protection of the Ozone Layer. United Nations Environment Programme, Nairobi, Kenya (1996).
15. Smyth HDC. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv. Drug Deliv. Rev. 55, 807-828 (2003). (Pubitemid 36776795)
16. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther. 16, 79-95 (2003). (Pubitemid 36372063)
17. Begat P, Price R, Harris H, Morton DAV, Staniforth JN. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. KONA 23, 109-120 (2005).
18. Weers JG, Tarara TE, Clark AR. Design of fine particles for pulmonary drug delivery. Expert Opin. Drug Deliv. 4(3), 297-313 (2007). (Pubitemid 46772848)
19. Jetmalani K, Stewart PJ, Traini D, Young PM. Formulation and characteristics of combination dry powder inhalation therapy. Resp. Drug Deliv. Eur. 2, 523-526 (2011).
20. Dubin CH. The state of systemic pulmonary delivery: one year after Exubera's approval. Drug Dev Technol. 7(4), 61-67 (2007).
21. Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray drying. J. Aerosol. Sci. 38(7), 728-746 (2007). (Pubitemid 47087809)
22. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm. Res. 24, 411-437 (2007).
23. Snyder HE, Lechuga-Ballesteros D. Spray drying: theory and pharmaceutical applications. In: Pharmaceutical Dosage Forms: Tablets. Augsburger LL, Hoag SW (Eds.).Informa Health Care, NY, USA (2008).
24. Feng AL, Boraey MA, Gwin MA, Finlay PR, Kueh PJ, Vehring R. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary delivery. Int. J. Pharm. 409, 155-163 (2011).
25. Lechuga-Ballesteros D, Charan C, Stults CLM et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J. Pharm. Sci. 97(1), 287-302 (2008).
26. Adhikari B, Howes T, Wood BJ, Bhandari BR. The effect of low molecular weight surfactants and proteins on surface stickiness of sucrose during powder formation through spray drying. J. Food Eng. 94, 135-143 (2009).
27. Kawakami K, Sumitani C, Yoshihashi Y, Yonemochi E, Terada K. Investigation of the dynamic process during spray-drying to improve aerodynamic performance of inhalation particles. Int. J. Pharm. 390, 250-259 (2010).
28. Westmeier R, Steckel H. Combination particles containing salmeterol xinafoate and fluticasone propionate: formulation and aerodynamic assessment. J. Pharm. Sci. 97, 2299 (2008).
29. Alhalaweh A, Velaga SP. Formation of cocrystals from stoichiometric solutions of incongruently saturating systems by spray drying. Cryst. Growth Design. 10(8), 3302-3305 (2010).
30. Harus-Frenkel O, Bivas-Benita M, Nassar T et al. A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. Tox. Appl. Pharmacol. 246, 83-90 (2010).
31. Kumon M, Kwok PCL, Adi H, Heng D, Chan H-K. Can low-dose combination products for inhalation be formulated in single crystalline particles? Eur. J. Pharm. Sci. 40, 16-24 (2010).
32. Geller DE, Weers JG, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J. Aerosol Med. Pulm. Drug Deliv. 24(4), 175-182 (2011).
33. Weers JG. Dispersible powders for inhalation applications. Innov. Pharm. Tech. 1, 111-116 (2000).
34. Duddu SP, Sisk SA, Walter YH et al. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharm. Res. 19(5), 689-695 (2002). (Pubitemid 34553679)
35. Weers JG, Tarara TE, Malcolmson R, Leung D. Embedded crystals in low density particles: formulation, manufacture, and properties. Resp. Drug Deliv. X, 297-306 (2006).
36. Tarara TE, Hartman MS, Gill H, Kennedy AA, Weers JG. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm. Res. 21(9), 1607-1614 (2004). (Pubitemid 41184391)
37. Kaerger JS, Price R. Processing of spherical crystalline particles via a novel solution atomization and crystallization by sonication (SAXS) technique. Pharm. Res. 21(2), 372-381 (2004). (Pubitemid 38221985)
38. Bell J, Newman SP. The rejuvenated pressurised metered dose inhaler. Expert Opin. Drug Deliv. 4(3), 215-234 (2007). (Pubitemid 46767625)
39. Rogueda P. Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Expert Opin. Drug Deliv. 2, 625-638 (2005). (Pubitemid 41038676)
40. Schultz RK. Drug delivery characteristics of metered-dose inhalers. J. Allergy Clin. Immunol. 96, 284-297 (1995).
41. Stein SW, Myrdal PB. A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions. J. Pharm. Sci. 93, 2158-2175 (2004). (Pubitemid 39045494)
42. Dhillon S, Keating GM. Beclometasone dipropionate / formoterol in an HFA-propelled pressurized metered -dose inhaler. Drugs 66, 1475-1486 (2006).
43. Lewis DA, Ganderton D, Meakin BJ, Brambilla G. Modulite®: a simple solution to a difficult problem. Respiration 72, 3-5 (2005). (Pubitemid 40868759)
44. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC- beclomethasone. Eur. Respir. J. 12, 1346-1353 (1998). (Pubitemid 29011427)
45. Michael Y, Snowden MJ, Chowdhry BZ, Ashurst IC, Davies-Cutting CJ, Riley T. Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system. Int. J. Pharm. 221(1-2), 165-174 (2001). (Pubitemid 32524045)
46. Michael Y, Chowdhry BZ, Ashurst IC, Snowden MJ, Davies-Cutting CJ, Gray S. The physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments. Int. J. Pharm. 200(2), 279-288 (2000). (Pubitemid 30364915)
47. Purohit D, Trehan A, Arora V. Development of room temperature stable formulation of formoterol fumarate/beclomethasone HFA pMDI. Ind. J. Pharm. Sci. 71(6), 713-715 (2009).
48. Steckel H, Wehle S. A novel formulation technique for metered dose inhaler (MDI) suspensions. Int. J. Pharm. 284, 75-82 (2004). (Pubitemid 39349141)
49. James J, Crean B, Davies M, Toon R, Jinks P, Roberts CJ. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. Int. J. Pharm. 36(1-2), 209-221 (2008).
50. Jinks PA, Bainbridge P. Room temperature stable formoterol metered dose inhaler systems with consistent delivery characteristics. In: Drug Delivery to the Lungs 18. The Aerosol Society, London, UK Poster 37 (2008).
51. Wu L, da Rocha SR. Nanoparticle-stabilized colloids in compressible hydrofluoroalkanes. Langmuir 27(17), 10501-10506 (2011).
52. Hirst PH, Pitcairn GR, Weers JG et al. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm. Res. 19(3), 258-264 (2002). (Pubitemid 34211841)
53. Dellamary LA, Tarara TE, Smith DJ et al. Hollow porous particles in metered dose inhalers. Pharm. Res. 17(2), 168-174 (2000). (Pubitemid 30158365)
54. Janiak MJ, Small DM, Shipley GG. Temperature and compositional dependence of the structure of hydrated dimyristoyl lecithin. J. Biol. Chem. 254, 6068-6078 (1979).
55. Hoe S, Traini D, Chan HK, Young PM. The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers. Pharm. Res. 26, 2639-2646 (2009).
56. Chambers F, Ludzik A. In vitro drug delivery performance of a new budesonide/ formoterol pressurized metered-dose inhaler. J. Aerosol Med. Pulm. Drug Deliv. 22(2), 113-120 (2009).
57. Lechuga-Ballesteros D, Vehring R, Dwivedi SK. A new co-suspension MDI platform: Scientific foundations of mono, dual and triple combination products. Resp. Drug Deliv. Eur. 1, 101-112 (2011).
58. Rooney SA. Phospholipid composition, biosynthesis, and secretion. In: Comparative Biology of the Normal Lung. Parent RA (Ed.).CRC Press, Boca Raton, FL, USA 511-544 (1992).
59. Joshi V, Lechuga-Ballesteros D, Flynn B et al. Development of mono, dual and triple combination pMDIs without co-formulation effect. Resp. Drug Deliv. Eur. 2, 383-386 (2011).
60. Cummings H, Schultz RD, Speck JH et al. Performance advantages of co-suspension formulation technology for manufacturing of metered dose inhalers. Resp. Drug Deliv. Eur. 2, 387-390 (2011).
61. Adams CP, van Branter V. C. P. Adams, V. Van Branter, Estimating the cost of new drug development: is it really $802 million? Health Affairs 25, 420-428 (2006). (Pubitemid 43529550)